{"id":35824,"date":"2025-08-06T17:31:15","date_gmt":"2025-08-06T21:31:15","guid":{"rendered":"https:\/\/www.cancerresearch.org\/?post_type=cri_scientists&#038;p=35824"},"modified":"2025-08-06T17:40:56","modified_gmt":"2025-08-06T21:40:56","slug":"nina-bhardwaj-md-phd-innovator","status":"publish","type":"cri_scientists","link":"https:\/\/www.cancerresearch.org\/es\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator","title":{"rendered":"Nina Bhardwaj, MD, PhD"},"content":{"rendered":"\n<p>Cancer is driven by genetic mutations that cause uncontrolled cell growth. Immunotherapies like neoantigen vaccines take advantage of these mutations to trigger targeted immune responses with fewer side effects. While this approach holds great promise, developing a personalized vaccine for every patient is costly and time- and labor- intensive. Dr. Nina Bhardwaj and colleagues are exploring a more practical solution: an \u201coff-the-shelf\u201d vaccine that targets mutations commonly shared across many patients.\u00a0<br><br>Non-muscle invasive bladder cancer (NMIBC) accounts for 75-80% of all newly diagnosed bladder cancers, and patients with intermediate- or high-risk NMIBC face high rates of recurrence and disease progression. Most intermediate-risk patients have mutations in the <em>FGFR3<\/em> gene, making it an ideal target for a shared vaccine approach. Prior studies have shown that <em>FGFR3<\/em> mutations can stimulate anti-tumor immune responses and that vaccines targeting these mutations can produce both clinical and immunologic benefits.\u00a0<br><br>This new clinical trial will evaluate two different FGFR3-targeted treatment strategies for patients with intermediate-risk NMIBC: 1) a vaccine targeting <em>FGFR3<\/em> mutations and 2) a novel slow-release bladder-inserted device (TAR-210) that delivers an FGFR3 inhibitor directly to the tumor. Patients will receive either TAR-210 alone or TAR-210 plus the vaccine to determine whether the combination improves outcomes. This innovative study aims to make targeted immunotherapy more accessible, durable, and scalable for patients with bladder cancer.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Projects and Grants<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Randomized phase 1b trial of shared FGFR3 neoantigen peptide vaccine in combination with TAR-210 or TAR-210 monotherapy for FGFR3-mutated intermediate-risk non\u2010muscle invasive bladder cancer<\/strong><\/h3>\n\n\n\n<h2 class=\"wp-block-heading\">Co-Investigators<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Jonathan Anker, MD, PhD<\/li>\n\n\n\n<li>Mesude Bicak, PhD<\/li>\n\n\n\n<li>Marcio Diniz, PhD<\/li>\n\n\n\n<li>Matthew Galsky, MD<\/li>\n\n\n\n<li>Mansi Saxena, PhD<\/li>\n\n\n\n<li>John Sfakianos, MD<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Cancer is driven by genetic mutations that cause uncontrolled cell growth. Immunotherapies like neoantigen vaccines take advantage of these mutations to trigger targeted immune responses with fewer side effects. While this approach [&hellip;]<\/p>\n","protected":false},"featured_media":35825,"template":"","tax_cancer_type":[355],"tax_grant_type":[725],"tax_award_year":[742],"tax_institutions":[540],"tax_location_states":[503],"class_list":["post-35824","cri_scientists","type-cri_scientists","status-publish","has-post-thumbnail","hentry"],"acf":{"scientist_subhead":"CRI Clinical Innovator","quote":"","scientist_last_name":"Bhardwaj","show_on_landing":false,"scientist_publish_until":"20280831"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nina Bhardwaj, MD, PhD - Cancer Research Institute<\/title>\n<meta name=\"description\" content=\"This new clinical trial will evaluate two different FGFR3-targeted treatment strategies for patients with intermediate-risk NMIBC: 1) a vaccine targeting FGFR3 mutations and 2) a novel slow-release bladder-inserted device (TAR-210) that delivers an FGFR3 inhibitor directly to the tumor. Patients will receive either TAR-210 alone or TAR-210 plus the vaccine to determine whether the combination improves outcomes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nina Bhardwaj, MD, PhD - Cancer Research Institute\" \/>\n<meta property=\"og:description\" content=\"This new clinical trial will evaluate two different FGFR3-targeted treatment strategies for patients with intermediate-risk NMIBC: 1) a vaccine targeting FGFR3 mutations and 2) a novel slow-release bladder-inserted device (TAR-210) that delivers an FGFR3 inhibitor directly to the tumor. Patients will receive either TAR-210 alone or TAR-210 plus the vaccine to determine whether the combination improves outcomes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator\" \/>\n<meta property=\"og:site_name\" content=\"Cancer Research Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-06T21:40:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Nina-Bhardwaj-Headshot-June-2025-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"8192\" \/>\n\t<meta property=\"og:image:height\" content=\"5464\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator\",\"url\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator\",\"name\":\"Nina Bhardwaj, MD, PhD - Cancer Research Institute\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Nina-Bhardwaj-Headshot-June-2025-1.jpg\",\"datePublished\":\"2025-08-06T21:31:15+00:00\",\"dateModified\":\"2025-08-06T21:40:56+00:00\",\"description\":\"This new clinical trial will evaluate two different FGFR3-targeted treatment strategies for patients with intermediate-risk NMIBC: 1) a vaccine targeting FGFR3 mutations and 2) a novel slow-release bladder-inserted device (TAR-210) that delivers an FGFR3 inhibitor directly to the tumor. Patients will receive either TAR-210 alone or TAR-210 plus the vaccine to determine whether the combination improves outcomes.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator#primaryimage\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Nina-Bhardwaj-Headshot-June-2025-1.jpg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Nina-Bhardwaj-Headshot-June-2025-1.jpg\",\"width\":8192,\"height\":5464},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancerresearch.org\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nina Bhardwaj, MD, PhD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancerresearch.org\/#website\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"name\":\"Cancer Research Institute\",\"description\":\"For a World Immune to Cancer\",\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancerresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\",\"name\":\"Cancer Research Institute\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"width\":156,\"height\":53,\"caption\":\"Cancer Research Institute\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nina Bhardwaj, MD, PhD - Cancer Research Institute","description":"This new clinical trial will evaluate two different FGFR3-targeted treatment strategies for patients with intermediate-risk NMIBC: 1) a vaccine targeting FGFR3 mutations and 2) a novel slow-release bladder-inserted device (TAR-210) that delivers an FGFR3 inhibitor directly to the tumor. Patients will receive either TAR-210 alone or TAR-210 plus the vaccine to determine whether the combination improves outcomes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator","og_locale":"es_ES","og_type":"article","og_title":"Nina Bhardwaj, MD, PhD - Cancer Research Institute","og_description":"This new clinical trial will evaluate two different FGFR3-targeted treatment strategies for patients with intermediate-risk NMIBC: 1) a vaccine targeting FGFR3 mutations and 2) a novel slow-release bladder-inserted device (TAR-210) that delivers an FGFR3 inhibitor directly to the tumor. Patients will receive either TAR-210 alone or TAR-210 plus the vaccine to determine whether the combination improves outcomes.","og_url":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator","og_site_name":"Cancer Research Institute","article_modified_time":"2025-08-06T21:40:56+00:00","og_image":[{"width":8192,"height":5464,"url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Nina-Bhardwaj-Headshot-June-2025-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator","url":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator","name":"Nina Bhardwaj, MD, PhD - Cancer Research Institute","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator#primaryimage"},"image":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Nina-Bhardwaj-Headshot-June-2025-1.jpg","datePublished":"2025-08-06T21:31:15+00:00","dateModified":"2025-08-06T21:40:56+00:00","description":"This new clinical trial will evaluate two different FGFR3-targeted treatment strategies for patients with intermediate-risk NMIBC: 1) a vaccine targeting FGFR3 mutations and 2) a novel slow-release bladder-inserted device (TAR-210) that delivers an FGFR3 inhibitor directly to the tumor. Patients will receive either TAR-210 alone or TAR-210 plus the vaccine to determine whether the combination improves outcomes.","breadcrumb":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator#primaryimage","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Nina-Bhardwaj-Headshot-June-2025-1.jpg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Nina-Bhardwaj-Headshot-June-2025-1.jpg","width":8192,"height":5464},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/nina-bhardwaj-md-phd-innovator#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancerresearch.org\/es"},{"@type":"ListItem","position":2,"name":"Nina Bhardwaj, MD, PhD"}]},{"@type":"WebSite","@id":"https:\/\/www.cancerresearch.org\/#website","url":"https:\/\/www.cancerresearch.org\/","name":"Cancer Research Institute","description":"For a World Immune to Cancer","publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancerresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cancerresearch.org\/#organization","name":"Cancer Research Institute","url":"https:\/\/www.cancerresearch.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","width":156,"height":53,"caption":"Cancer Research Institute"},"image":{"@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/"}}]}},"fimg_url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Nina-Bhardwaj-Headshot-June-2025-1.jpg","_links":{"self":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_scientists\/35824","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_scientists"}],"about":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/types\/cri_scientists"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media\/35825"}],"wp:attachment":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media?parent=35824"}],"wp:term":[{"taxonomy":"tax_cancer_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_cancer_type?post=35824"},{"taxonomy":"tax_grant_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_grant_type?post=35824"},{"taxonomy":"tax_award_year","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_award_year?post=35824"},{"taxonomy":"tax_institutions","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_institutions?post=35824"},{"taxonomy":"tax_location_states","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_location_states?post=35824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}